Renal Mass Biopsies May Help Patients Bypass Surgery

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 2
Volume 19
Issue 2

Using renal mass biopsy to guide treatment decisions for small tumors is cost-effective relative to direct surgery, and can spare many patients unnecessary surgical procedures, according to Massachusetts General Hospital researchers.

Using renal mass biopsy to guide treatment decisions for small tumors is cost-effective relative to direct surgery, and can spare many patients unnecessary surgical procedures, according to Massachusetts General Hospital researchers.

Most small renal masses are detected incidentally in imaging and their current treatment is direct surgery, said lead researcher Pari Pandharipande, MD, a radiologist in the abdominal imaging and interventional radiology department at MGH. Many small renal masses, however, are benign-or indolent if they are malignant-and so less invasive management strategies should be considered, she said.

After constructing a decision-analytic Markov model, the researchers determined surgery was about $3,500 more expensive than biopsy and resulted in a comparable minimally lower life expectancy. Biopsy therefore dominated surgery from a cost-effectiveness perspective (RSNA 2009 abstract SSG09-04).

The researchers assumed a biopsy sensitivity of 90% and specificity of 100%. The researchers also assumed a postsurgery mortality rate of 1.6%. Among imaging-detected masses, 77% were assumed to reflect renal cell carcinoma. Biopsy did not dominate surgery under some conditions, for example, when sensitivity was lower than 78%, when surgical mortality was less than 1%, and when prevalence of renal cancer was greater than 87%.

The researchers used a competing choices cost-effectiveness analysis to compare biopsy with surgery. If one strategy had a lower life expectancy and a higher cost than another, it was considered dominated. If not, an incremental cost-effectiveness ratio was computed and strategy preference was assessed based on an assumed $75,000 per quality adjusted life year societal willingness-to-pay threshold.

The long-term outcomes of life expectancy and lifetime costs after biopsy and surgery were estimated by using a decision-analytic Markov model. The cohort in the base-case analysis was 65-year-old men with incidental renal masses. All patients started with small incidental renal masses and underwent either surgery or biopsy. Patients receiving biopsy could have a true or false-positive or false-negative result. Patients with negative biopsy results underwent CT surveillance for up to five years. Patients with positive and nondiagnostic biopsy specimens underwent direct surgery.

Recent Videos
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Related Content